P095 amiselimod safety profile for crohn ’s disease, stratified by previous treatment with anti-tnf agents

Anti-TNF agents are an established treatment modality for ulcerative colitis (UC); however, as many as 30% of patients do not respond to anti-TNF agents, and almost 50% of responders lose clinical benefits after a year of treatment. Furthermore, numerous safety concerns are associated with long-term use of anti-TNF agents. An alternative treatment in development for autoimmune-mediated diseases, including Crohn ’s disease (CD) and UC, are sphingosine 1-phosphate receptor modulators such as amiselimod (AMS).
Source: Gastroenterology - Category: Gastroenterology Authors: Tags: Adverse Events Related to Therapy Source Type: research